Epizyme Shares Down 9% Despite Accelerated FDA Approval For Its Epithelioid Sarcoma Treatment; Wedbush Analyst David Nierengarten Attributes Move To Potential 'Sell On The News' Response As Well Potential Lower-Than-Expected Pricing Of The Drug